StockNews.com began coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research report released on Saturday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, August 15th. Read […]
HC Wainwright reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.16) EPS, […]
Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) EPS, Q4 […]
Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) […]
StockNews.com started coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the stock. Galectin Therapeutics Stock Up 4.3 % Shares of NASDAQ GALT traded up $0.06 during trading on Thursday, hitting $1.45. The company had a trading […]